Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Nucleic Acids Res ; 48(14): 7973-7980, 2020 08 20.
Article in English | MEDLINE | ID: mdl-32597964

ABSTRACT

Coordinating multiple activities of complex enzymes is critical for life, including transcribing, replicating and repairing DNA. Bacterial RecBCD helicase-nuclease must coordinate DNA unwinding and cutting to repair broken DNA. Starting at a DNA end, RecBCD unwinds DNA with its fast RecD helicase on the 5'-ended strand and its slower RecB helicase on the 3'-ended strand. At Chi hotspots (5' GCTGGTGG 3'), RecB's nuclease cuts the 3'-ended strand and loads RecA strand-exchange protein onto it. We report that a small molecule NSAC1003, a sulfanyltriazolobenzimidazole, mimics Chi sites by sensitizing RecBCD to cut DNA at a Chi-independent position a certain percent of the DNA substrate's length. This percent decreases with increasing NSAC1003 concentration. Our data indicate that NSAC1003 slows RecB relative to RecD and sensitizes it to cut DNA when the leading helicase RecD stops at the DNA end. Two previously described RecBCD mutants altered in the RecB ATP-binding site also have this property, but uninhibited wild-type RecBCD lacks it. ATP and NSAC1003 are competitive; computation docks NSAC1003 into RecB's ATP-binding site, suggesting NSAC1003 acts directly on RecB. NSAC1003 will help elucidate molecular mechanisms of RecBCD-Chi regulation and DNA repair. Similar studies could help elucidate other DNA enzymes with activities coordinated at chromosomal sites.


Subject(s)
Benzimidazoles/pharmacology , Enzyme Inhibitors/pharmacology , Exodeoxyribonuclease V/antagonists & inhibitors , Adenosine Triphosphate/metabolism , Benzimidazoles/chemistry , Binding Sites , Enzyme Inhibitors/chemistry , Exodeoxyribonuclease V/chemistry , Exodeoxyribonuclease V/genetics , Exodeoxyribonuclease V/metabolism , Mutation
2.
ACS Chem Biol ; 7(5): 879-91, 2012 May 18.
Article in English | MEDLINE | ID: mdl-22443934

ABSTRACT

The AddAB and RecBCD helicase-nucleases are related enzymes prevalent among bacteria but not eukaryotes and are instrumental in the repair of DNA double-strand breaks and in genetic recombination. Although these enzymes have been extensively studied both genetically and biochemically, inhibitors specific for this class of enzymes have not been reported. We developed a high-throughput screen based on the ability of phage T4 gene 2 mutants to grow in Escherichia coli only if the host RecBCD enzyme, or a related helicase-nuclease, is inhibited or genetically inactivated. We optimized this screen for use in 1536-well plates and screened 326,100 small molecules in the NIH molecular libraries sample collection for inhibitors of the Helicobacter pylori AddAB enzyme expressed in an E. coli recBCD deletion strain. Secondary screening used assays with cells expressing AddAB or RecBCD and a viability assay that measured the effect of compounds on cell growth without phage infection. From this screening campaign, 12 compounds exhibiting efficacy and selectivity were tested for inhibition of purified AddAB and RecBCD helicase and nuclease activities and in cell-based assays for recombination; seven were active in the 0.1-50 µM range in one or another assay. Compounds structurally related to two of these were similarly tested, and three were active in the 0.1-50 µM range. These compounds should be useful in further enzymatic, genetic, and physiological studies of these enzymes, both purified and in cells. They may also lead to useful antibacterial agents, since this class of enzymes is needed for successful bacterial infection of mammals.


Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Escherichia coli/enzymology , Exodeoxyribonuclease V/antagonists & inhibitors , Exodeoxyribonucleases/antagonists & inhibitors , Helicobacter pylori/enzymology , High-Throughput Screening Assays/methods , Microbial Sensitivity Tests/methods , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology
3.
EMBO J ; 26(15): 3662-72, 2007 Aug 08.
Article in English | MEDLINE | ID: mdl-17627281

ABSTRACT

Protection from NO gas, a toxic byproduct of anaerobic respiration in Pseudomonas aeruginosa, is mediated by nitric oxide (NO) reductase (NOR), the norCB gene product. Nevertheless, a norCB mutant that accumulated approximately 13.6 microM NO paradoxically survived anaerobic growth. Transcription of genes encoding nitrate and nitrite reductases, the enzymes responsible for NO production, was reduced >50- and 2.5-fold in the norCB mutant. This was due, in part, to a predicted compromise of the [4Fe-4S](2+) cluster in the anaerobic regulator ANR by physiological NO levels, resulting in an inability to bind to its cognate promoter DNA sequences. Remarkably, two O(2)-dependent dioxygenases, homogentisate-1,2-dioxygenase (HmgA) and 4-hydroxyphenylpyruvate dioxygenase (Hpd), were derepressed in the norCB mutant. Electron paramagnetic resonance studies showed that HmgA and Hpd bound NO avidly, and helped protect the norCB mutant in anaerobic biofilms. These data suggest that protection of a P. aeruginosa norCB mutant against anaerobic NO toxicity occurs by both control of NO supply and reassignment of metabolic enzymes to the task of NO sequestration.


Subject(s)
Cystic Fibrosis/microbiology , Nitric Oxide/metabolism , Pseudomonas aeruginosa/physiology , Anaerobiosis , Bacterial Proteins/genetics , Bacterial Proteins/physiology , Electrophoresis, Gel, Two-Dimensional , Mutation , Pseudomonas aeruginosa/growth & development , Pseudomonas aeruginosa/metabolism , Spectrum Analysis/methods , Transcription, Genetic
4.
J Clin Invest ; 116(2): 436-46, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16440061

ABSTRACT

Mucoid, mucA mutant Pseudomonas aeruginosa cause chronic lung infections in cystic fibrosis (CF) patients and are refractory to phagocytosis and antibiotics. Here we show that mucoid bacteria perish during anaerobic exposure to 15 mM nitrite (NO2) at pH 6.5, which mimics CF airway mucus. Killing required a pH lower than 7, implicating formation of nitrous acid (HNO2) and NO, that adds NO equivalents to cellular molecules. Eighty-seven percent of CF isolates possessed mucA mutations and were killed by HNO2 (3-log reduction in 4 days). Furthermore, antibiotic-resistant strains determined were also equally sensitive to HNO2. More importantly, HNO2 killed mucoid bacteria (a) in anaerobic biofilms; (b) in vitro in ultrasupernatants of airway secretions derived from explanted CF patient lungs; and (c) in mouse lungs in vivo in a pH-dependent fashion, with no organisms remaining after daily exposure to HNO2 for 16 days. HNO2 at these levels of acidity and NO2 also had no adverse effects on cultured human airway epithelia in vitro. In summary, selective killing by HNO2 may provide novel insights into the important clinical goal of eradicating mucoid P. aeruginosa from the CF airways.


Subject(s)
Cystic Fibrosis/metabolism , Drug Resistance, Bacterial , Nitrites/metabolism , Pseudomonas aeruginosa/metabolism , Anaerobiosis , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biofilms , Cells, Cultured , Child , Child, Preschool , Cystic Fibrosis/microbiology , Epithelial Cells/cytology , Humans , Hydrogen-Ion Concentration , Infant , Mice , Microbial Sensitivity Tests , Mucus/chemistry , Pseudomonas Infections , Pseudomonas aeruginosa/genetics , Respiratory Mucosa/cytology , Sputum/chemistry , Sputum/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL